I recently received a great question about the use of dexmedetomidine for acute agitation. With its recent FDA approval for agitation associated with bipolar disorder and schizophrenia, it’s only natural to wonder: is this the new go-to treatment, or just another overhyped medication?
Let’s start with the obvious. New medications almost always come with a hefty price tag. That cost is only justifiable if they outperform existing options in either efficacy or safety—and in this case, dexmedetomidine falls short on both fronts.
Current data suggest it does not provide superior outcomes when compared to existing, well-established medications like lorazepam, haloperidol, or olanzapine. And it brings along its own baggage: bradycardia, hypotension, and sedation-related complications that can be clinically significant, especially in medically complex patients.
When you combine the high cost with a safety profile that raises some red flags—and no clear advantage in efficacy—it becomes hard to justify widespread use.
For now, I’d place dexmedetomidine in the “hype” category. We already have effective, affordable options with strong track records in managing acute agitation. Until further data prove otherwise, there’s little reason to switch.
Leave a Reply